104 results
8-K
EX-99.1
STRO
Sutro Biopharma Inc
13 May 24
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995
8-K
STRO
Sutro Biopharma Inc
2 Apr 24
Entry into a Material Definitive Agreement
5:10pm
harbor” provisions of the Private Securities Litigation Reform Act of 1995, and other federal securities laws. Any statements contained herein that do
8-K
EX-1.1
STRO
Sutro Biopharma Inc
2 Apr 24
Entry into a Material Definitive Agreement
5:10pm
Laws or Regulatory Authorizations and has no knowledge that the Applicable Regulatory Authorities is considering any such claim, litigation, arbitration
424B5
22c6tl3c
2 Apr 24
Prospectus supplement for primary offering
4:58pm
8-K
9kp59k8usalie hak
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
8-K
EX-99.1
hbzpd01hotccj0fi
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
8-K
EX-99.1
skklj
25 Mar 24
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm
8-K
EX-1.1
cf6haf40a1jal
9 Feb 24
Other Events
4:27pm
424B5
jeclbsrf k1kd7x
9 Feb 24
Prospectus supplement for primary offering
4:25pm
8-K
axj9uixjhe g9
8 Jan 24
Results of Operations and Financial Condition
7:31am
8-K
EX-99.1
l81b 3rsnto
21 Nov 23
Departure of Directors or Certain Officers
4:05pm
8-K
EX-99.1
2g2gdota90eldtg aclp
13 Nov 23
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
4:30pm